Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies

Virology

Volumn 385, Issue 1, 2009, Pages 11-21

  Parker, Scott ^a   Siddiqui, Akbar M ^a   Oberle, Christina ^a   Hembrador, Ed ^a   Lanier, Randall ^b   Painter, George ^b   Robertson, Alice ^b   Buller, R Mark ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Chimerix Inc   (United States)

Author keywords

Antiviral; Bioterrorism; Cidofovir; Ectromelia; Oral drug; Smallpox

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CMX 001; GAMMA INTERFERON; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ECTROMELIA VIRUS; FEMALE; LOADING DRUG DOSE; MORTALITY; MOUSE; MOUSEPOX; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SMALLPOX; TH1 CELL; THERAPY DELAY; VIROTHERAPY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOKINES; CYTOSINE; DISEASE MODELS, ANIMAL; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; FEMALE; MICE; MICE, INBRED C57BL; PHOSPHONIC ACIDS;

ECTROMELIA VIRUS; MONKEYPOX VIRUS; MUS; ORTHOPOXVIRUS; POXVIRIDAE; VARIOLA; VARIOLA VIRUS;

EID: 60649099358     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.11.015     Document Type: Article

References (45)

1. Baker R.O., Bray M., and Huggins J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res. 57 (2003) 13-23
2. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antivir. Res. 58 (2003) 101-114
3. Buller R.M., Owens G., Schriewer J., Melman L., Beadle J.R., and Hostetler K.Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318 (2004) 474-481
4. Chaudhri G., Panchanathan V., Buller R.M., van den Eertwegh A.J., Claassen E., Zhou J., de Chazal R., Laman J.D., and Karupiah G. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9057-9062
5. Chen W., Drillien R., Spehner D., and Buller R.M. Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene. Virology 187 (1992) 433-442
6. Cunha B.E. Monkeypox in the United States: an occupational health look at the first cases. AAOHN J. 52 (2004) 164-168
7. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antivir. Res. 55 (2002) 1-13
8. Fenner F., Henderson D.A., Arita I., Jezek Z., and Ladnyi I.D. Smallpox and Its Eradication (1988), World Health Organisation, Geneva
9. Heinzel F.P., Sadick M.D., Mutha S.S., and Locksley R.M. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 7011-7015
10. Hosack D.A., Dennis Jr. G., Sherman B.T., Lane H.C., and Lempicki R.A. Identifying biological themes within lists of genes with EASE. Genome Biol. 4 (2003) R70
11. Huang D.W., Sherman B.T., Tan Q., Kir J., Liu D., Bryant D., Guo Y., Stephens R., Baseler M.W., Lane H.C., and Lempicki R.A. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 35 (2007) W169-W175
12. Huhn G.D., Bauer A.M., Yorita K., Graham M.B., Sejvar J., Likos A., Damon I.K., Reynolds M.G., and Kuehnert M.J. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin. Infect. Dis. 41 (2005) 1742-1751
13. Kameyoshi Y., Matsushita M., and Okada H. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase. Immunology 68 (1989) 439-444
14. Kern E.R., Hartline C., Harden E., Keith K., Rodriguez N., Beadle J.R., and Hostetler K.Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46 (2002) 991-995
15. Kuna P., Reddigari S.R., Schall T.J., Rucinski D., Viksman M.Y., and Kaplan A.P. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J. Immunol. 149 (1992) 636-642
16. Maghazachi A.A., Al Aoukaty A., and Schall T.J. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. J. Immunol. 153 (1994) 4969-4977
17. Mortimer P.P. Anticipating smallpox as a bioterrorist weapon. Clin. Med. 3 (2003) 255-259
18. Mortimer P.P. Can postexposure vaccination against smallpox succeed?. Clin. Infect. Dis. 36 (2003) 622-629
19. Moss B.A.E.P.L. Expression of proteins in mammalian cells using vaccinia cirus vectors. Overview of the vaccinia virus expression system. Current Protocols in Molecular Biology (1998), Wiley 16.15.1-16.15.5.
20. Paran, N., Suezer, Y., Lustig, S., Israely, T., Schwantes, A., Melamed, S., Katz, L., Preuß, T., Hanschmann, K.M., Kalinke, U., Erez, N., Levin, R., Velan, B., Löwer, J., Shafferman, A., Sutter, G., in press. Postexposure Immunization with Modified Vaccinia Virus Ankara or Conventional Lister Vaccine Provides Solid Protection in a Murine Model of Human Smallpox. J. Infect Dis. (Nov 14 [Electronic publication ahead of print]).
21. Parker A.K., Parker S., Yokoyama W.M., Corbett J.A., and Buller R.M. Induction of natural killer cell responses by ectromelia virus controls infection. J.Virol. 81 (2007) 4070-4079
22. Parker S., Nuara A., Buller R.M., and Schultz D.A. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2 (2007) 17-34
23. Parker S., Schultz D.A., Meyer H., and Buller R.L. Smallpox and monkeypox viruses. In: Mahy B.W.J., and Van Ragenmortel N.H.V. (Eds). Encyclopedia of Virology vol. 4 (2008) 639-644
24. Parker S., Touchette E., Oberle C., Almond M., Robertson A., Trost L.C., Lampert B., Painter G., and Buller R.M. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antivir. Res. 77 (2008) 39-49
25. Parker S., Schriewer J., Oberle C., Robertson A., Lanier R., Painter G., and Buller R.M. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antiviral Therapy 13 (2008) 863-873
26. Pavlidis P. Using ANOVA for gene selection from microarray studies of the nervous system. Methods 31 (2003) 282-289
27. Quenelle D.C., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., and Kern E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48 (2004) 404-412
28. Quenelle D.C., Buller R.M., Parker S., Keith K.A., Hruby D.E., Jordan R., and Kern E.R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51 (2007) 689-695
29. Reed L.J., and Muench H.A. A simple method of estimating fifty percent endpoints. Am. J. Hygiene 27 (1938) 493-497
30. Reed K.D., Melski J.W., Graham M.B., Regnery R.L., Sotir M.J., Wegner M.V., Kazmierczak J.J., Stratman E.J., Li Y., Fairley J.A., Swain G.R., Olson V.A., Sargent E.K., Kehl S.C., Frace M.A., Kline R., Foldy S.L., Davis J.P., and Damon I.K. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350 (2004) 342-350
31. Reiner A., Yekutieli D., and Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19 (2003) 368-375
32. Safrin S., Cherrington J., and Jaffe H.S. Clinical uses of cidofovir. Rev. Med. Virol. 7 (1997) 145-156
33. Samuelsson C., Hausmann J., Lauterbach H., Schmidt M., Akira S., Wagner H., Chaplin P., Suter M., O'Keeffe M., and Hochrein H. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118 (2008) 1776-1784
34. Schall T.J., Bacon K., Toy K.J., and Goeddel D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347 (1990) 669-671
35. Schell K. Studies on the innate resistance of mice to infection with mouse-pox. II. Route of inoculation and resistance: and some observations on the inheritance of resistance. Aust. J. Exp. Biol. Med. Sci. 38 (1960) 289-299
36. Sejvar J.J., Chowdary Y., Schomogyi M., Stevens J., Patel J., Karem K., Fischer M., Kuehnert M.J., Zaki S.R., Paddock C.D., Guarner J., Shieh W.J., Patton J.L., Bernard N., Li Y., Olson V.A., Kline R.L., Loparev V.N., Schmid D.S., Beard B., Regnery R.R., and Damon I.K. Human monkeypox infection: a family cluster in the midwestern United States. J. Infect. Dis. 190 (2004) 1833-1840
37. Sherman B.T., Huang D.W., Tan Q., Guo Y., Bour S., Liu D., Stephens R., Baseler M.W., Lane H.C., and Lempicki R.A. DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics 8 (2007) 426
38. Spellberg B., and Edwards Jr. J.E. Type 1/Type 2 immunity in infectious diseases. Clin. Infect. Dis. 32 (2001) 76-102
39. Wallace G.D., and Buller R.M. Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice. Lab. Anim. Sci. 35 (1985) 41-46
40. Wu Z., and Irizarry R.A. Preprocessing of oligonucleotide array data. Nat. Biotechnol. 22 (2004) 656-658
41. Wu Z., and Irizarry R.A. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J. Comput. Biol. 12 (2005) 882-893
42. Wu H., Wang H., Xiong W., Chen S., Tang H., and Han D. Expression patterns and functions of Toll-like receptors in mouse Sertoli cells. Endocrinology 49 9 (2008) 4402-4412 (Epub 2008 May 22)
43. Wu-Hsieh B. Relative susceptibilities of inbred mouse strains C57BL/6 and A/J to infection with Histoplasma capsulatum. Infect. Immun. 57 (1989) 3788-3792
44. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., and Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 79 (2005) 13139-13149
45. Zaunders J.J., Dyer W.B., Munier M.L., Ip S., Liu J., Amyes E., Rawlinson W., De Rose R., Kent S.J., Sullivan J.S., Cooper D.A., and Kelleher A.D. CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells. J. Virol. 80 (2006) 10151-10161